Opsona Therapeutics Ltd (‘Opsona’), today announces that it will give an oral presentation on results from its ongoing prospective, open label Phase I/II study being conducted with Tomaralimab (OPN-305), its novel proprietary humanized IgG4 monoclonal antibody (MAb) against Toll-Like Receptor 2 (TLR2), in second and third-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS). The presentation will take place on Dec 03rd 2018 at the 60th Annual Meeting of the American Society of Hematology (ASH) in San Diego.
Opsona Therapeutics Ltd. to present results on Tomaralimab study at the 60th Annual Meeting of the American Society of Hematology (ASH)
EMBL Ventures Portfolio Company, ViraTherapeutics, acquired by Boehringer Ingelheim in EUR 210 million (USD 245 million) transaction.
EMBL Ventures has been a strong supporter of ViraTherapeutics’ growth and development since having first invested in the Company in 2015 as part of its Series A financing round. EMBL Ventures’ interest in ViraTherapeutics focuses on the unique properties of its oncolytic (cancer-destroying) virus- based immunotherapy VSV-GP – a Vesicular Stomatitis Virus (VSV) with a modified glycoprotein (GP) - currently in advanced pre-clinical development for the treatment of solid tumours.
ViraTherapeutics sale marks third exit from EMBL Ventures’ current fund ETF II.
Crescendo Biologics Appoints Dr Pavel Pisa as Chief Medical Officer
Crescendo Biologics Strengthens its Management with the Appointment of Dr Pavel Pisa as Chief Medical Officer.